Evidence map›Paper›PMID 33336223›Full record

Trial reportThe journal of prevention of Alzheimer's disease2021

Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults.

W-H Lu, K V Giudici, Y Rolland, S Guyonnet, Y Li, R J Bateman, P de Souto Barreto, B Vellas

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journal of prevention of Alzheimer's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

W-H LuWan-Hsuan Lu, MS, Postal address: Gérontopôle de Toulouse, Institut du Vieillissement, 37 Allée Jules Guesde, 31000 Toulouse, France, E-mail address: wanhsuanlu@gmail.com, Phone number: +33-561-145-691.
K V Giudici
Y Rolland
S Guyonnet
Y Li
R J Bateman
P de Souto Barreto
B Vellas
Laboratoire Epidémiologie et Analyses en Santé Publique : Risques, Maladies Chroniques et Handicaps · FRWashington University in St. Louis · USInserm · FRMédipole Garonne · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

Blood amyloid-beta relationship with amyloid plaques and CSF amyloid-betaRF1AG061900 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2019 to 2020
$6.9M
Blood amyloid-beta relationship with amyloid plaques and CSF amyloid-betaR56AG061900 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2018 to 2018
$1.4M
NIA NIH HHS R56 AG061900NIA NIH HHS RF1 AG061900
6 · The paper itself

Abstract

backgroundBrain amyloid-beta (Aβ) plaques, a hallmark of the pathophysiology of Alzheimer's disease, have been associated with frailty. Whether the plasma Aβ markers show similar relationship with frailty is unknown.

objectivesTo investigate the prospective associations between plasma Aβ42/40 ratio and overtime frailty in community-dwelling older adults.

methodsFrom the 5-year Multidomain Alzheimer Preventive Trial (MAPT), we included 477 adults ≥70 years with available data on plasma Aβ42/40 ratio (lower is worse). Fried frailty phenotype (robust, pre-frail and frail) was assessed at the same time-point of plasma Aβ measures and after until the end of follow-up. The outcomes of interest were the change in the frailty phenotype over time (examined by mixed-effect ordinal logistic regressions) and incident frailty (examined by Cox proportional hazard models).

resultsPlasma Aβ42/40 did not show significant associations with incident frailty; however, after adjusting for Apolipoprotein E (APOE) ε4 genotype, people in the lower quartile of plasma Aβ42/40 (≤0.103) had higher risk of incident frailty (HR=2.63; 95% CI, 1.00 to 6.89), compared to those in the upper quartile (>0.123). Exploratory analysis found a significant association between the lower quartile of plasma Aβ42/40 and incident frailty among APOE ε4 non-carriers (HR=3.48; 95% CI, 1.19 to 10.16), but not among carriers. No associations between plasma Aβ42/40 and evolution of frailty were observed.

conclusionNo significant associations between plasma Aβ42/40 and frailty were found when APOE ε4 status was not accounted into the model. Nevertheless, APOE ε4 non-carriers with high Aβ burden might be more susceptible to develop frailty.

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesApolipoprotein E4BiomarkersDisease ProgressionFemaleFollow-Up StudiesFrailtyHumansIndependent LivingLongitudinal StudiesMalePeptide FragmentsProportional Hazards ModelsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4BiomarkersPeptide Fragmentsamyloid-betabiomarkerFrailtyneurodegenerationolder adults

Identifiers

PMID33336223
PMCPMC9982745
OpenAlexW3099887452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.